- Home
- DSGN vs ARAI Comparison
DSGN vs ARAI Comparison
Compare DSGN & ARAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- ARAI
- Stock Information
- Founded
- DSGN 2017
- ARAI 2020
- Country
- DSGN United States
- ARAI United States
- Employees
- DSGN N/A
- ARAI N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- ARAI Diversified Commercial Services
- Sector
- DSGN Health Care
- ARAI Finance
- Exchange
- DSGN Nasdaq
- ARAI Nasdaq
- Market Cap
- DSGN 208.9M
- ARAI 213.7M
- IPO Year
- DSGN 2021
- ARAI N/A
- Fundamental
- Price
- DSGN $6.03
- ARAI $3.60
- Analyst Decision
- DSGN
- ARAI
- Analyst Count
- DSGN 0
- ARAI 0
- Target Price
- DSGN N/A
- ARAI N/A
- AVG Volume (30 Days)
- DSGN 171.5K
- ARAI 233.5K
- Earning Date
- DSGN 11-06-2025
- ARAI 08-14-2025
- Dividend Yield
- DSGN N/A
- ARAI N/A
- EPS Growth
- DSGN N/A
- ARAI N/A
- EPS
- DSGN N/A
- ARAI N/A
- Revenue
- DSGN N/A
- ARAI $90,725.00
- Revenue This Year
- DSGN N/A
- ARAI N/A
- Revenue Next Year
- DSGN N/A
- ARAI N/A
- P/E Ratio
- DSGN N/A
- ARAI N/A
- Revenue Growth
- DSGN N/A
- ARAI N/A
- 52 Week Low
- DSGN $2.60
- ARAI $3.25
- 52 Week High
- DSGN $7.77
- ARAI $40.00
- Technical
- Relative Strength Index (RSI)
- DSGN 58.00
- ARAI N/A
- Support Level
- DSGN $5.65
- ARAI N/A
- Resistance Level
- DSGN $6.65
- ARAI N/A
- Average True Range (ATR)
- DSGN 0.51
- ARAI 0.00
- MACD
- DSGN -0.00
- ARAI 0.00
- Stochastic Oscillator
- DSGN 64.27
- ARAI 0.00
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About ARAI Arrive AI Inc. Common Stock
Arrive AI Inc is a technology company. Its patented Autonomous Last Mile (ALM) platform enables secure, efficient delivery to and from a smart, AI-powered mailbox-whether by drone, ground robot, or human courier. The platform provides real-time tracking, smart logistics alerts, and advanced chain-of-custody controls to support shippers, delivery services, and autonomous networks. By combining artificial intelligence with autonomous technology, Arrive AI makes the exchange of goods between people, robots, and drones frictionless and convenient. Its system integrates with smart home devices such as doorbells, lighting, and security systems to streamline the entire last-mile delivery experience.